CRISPR Therapeutics AG (LON:0VRQ)
London
· Delayed Price · Currency is GBP · Price in USD 49.18
+0.19 (0.39%)
At close: Jul 1, 2025
CRISPR Therapeutics AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 37.68 | 37.31 | 371.21 | 1.2 | 914.96 | 0.72 | Upgrade
| |
Revenue Growth (YoY) | -86.13% | -89.95% | 30885.48% | -99.87% | 127154.94% | -99.75% | Upgrade
|
Cost of Revenue | 437.76 | 430.9 | 517.58 | 571.9 | 441.75 | 269.41 | Upgrade
|
Gross Profit | -400.08 | -393.59 | -146.38 | -570.7 | 473.22 | -268.69 | Upgrade
|
Selling, General & Admin | 74.32 | 72.98 | 76.16 | 102.46 | 99.69 | 85.75 | Upgrade
|
Operating Expenses | 74.32 | 72.98 | 76.16 | 102.46 | 99.69 | 85.75 | Upgrade
|
Operating Income | -474.4 | -466.57 | -222.54 | -673.16 | 373.53 | -354.44 | Upgrade
|
Interest & Investment Income | 92.72 | 103.9 | 71.82 | 22.66 | 6 | - | Upgrade
|
Other Non Operating Income (Expenses) | - | - | - | - | - | 6.38 | Upgrade
|
EBT Excluding Unusual Items | -381.69 | -362.67 | -150.72 | -650.5 | 379.53 | -348.06 | Upgrade
|
Pretax Income | -381.69 | -362.67 | -150.72 | -650.5 | 379.53 | -348.06 | Upgrade
|
Income Tax Expense | 3.97 | 3.59 | 2.89 | -0.33 | 1.87 | 0.81 | Upgrade
|
Earnings From Continuing Operations | -385.66 | -366.25 | -153.61 | -650.18 | 377.66 | -348.87 | Upgrade
|
Net Income | -385.66 | -366.25 | -153.61 | -650.18 | 377.66 | -348.87 | Upgrade
|
Net Income to Common | -385.66 | -366.25 | -153.61 | -650.18 | 377.66 | -348.87 | Upgrade
|
Shares Outstanding (Basic) | 85 | 84 | 79 | 78 | 76 | 66 | Upgrade
|
Shares Outstanding (Diluted) | 85 | 84 | 79 | 78 | 80 | 66 | Upgrade
|
Shares Change (YoY) | 6.74% | 6.49% | 1.90% | -3.29% | 21.90% | 15.84% | Upgrade
|
EPS (Basic) | -4.52 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | Upgrade
|
EPS (Diluted) | -4.52 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | Upgrade
|
Free Cash Flow | -307.86 | -144.68 | -269.85 | -532.93 | 457.27 | -256.72 | Upgrade
|
Free Cash Flow Per Share | -3.60 | -1.72 | -3.41 | -6.86 | 5.69 | -3.89 | Upgrade
|
Gross Margin | - | - | -39.43% | - | 51.72% | - | Upgrade
|
Operating Margin | -1259.20% | -1250.38% | -59.95% | -56190.40% | 40.82% | -49295.55% | Upgrade
|
Profit Margin | -1023.64% | -981.54% | -41.38% | -54271.70% | 41.28% | -48520.86% | Upgrade
|
Free Cash Flow Margin | -817.14% | -387.72% | -72.69% | -44484.89% | 49.98% | -35705.70% | Upgrade
|
EBITDA | -455.24 | -447.31 | -202.7 | -648.99 | 391.48 | -345.25 | Upgrade
|
EBITDA Margin | - | - | -54.61% | - | 42.79% | - | Upgrade
|
D&A For EBITDA | 19.16 | 19.26 | 19.84 | 24.17 | 17.95 | 9.18 | Upgrade
|
EBIT | -474.4 | -466.57 | -222.54 | -673.16 | 373.53 | -354.44 | Upgrade
|
EBIT Margin | - | - | -59.95% | - | 40.82% | - | Upgrade
|
Effective Tax Rate | - | - | - | - | 0.49% | - | Upgrade
|
Revenue as Reported | 37.68 | 37.31 | 371.21 | 1.2 | 914.96 | 0.72 | Upgrade
|
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.